Aptose Biosciences (NASDAQ:APTO) Stock Rating Upgraded by StockNews.com

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Thursday.

Several other research analysts have also recently issued reports on the stock. Piper Sandler reduced their target price on shares of Aptose Biosciences from $12.00 to $5.00 and set an “overweight” rating for the company in a report on Thursday, February 1st. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Aptose Biosciences in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.80.

Aptose Biosciences Price Performance

APTO traded up $0.16 during trading on Thursday, reaching $1.66. 136,730 shares of the company’s stock were exchanged, compared to its average volume of 91,949. Aptose Biosciences has a 1 year low of $1.36 and a 1 year high of $9.90. The company’s fifty day simple moving average is $1.82 and its 200-day simple moving average is $2.35. The stock has a market capitalization of $26.10 million, a P/E ratio of -0.22 and a beta of 1.30.

Institutional Investors Weigh In On Aptose Biosciences

Several hedge funds have recently modified their holdings of APTO. Citadel Advisors LLC raised its stake in shares of Aptose Biosciences by 256.6% during the 4th quarter. Citadel Advisors LLC now owns 61,875 shares of the biotechnology company’s stock worth $155,000 after buying an additional 44,522 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new position in Aptose Biosciences during the fourth quarter worth $32,000. Annandale Capital LLC raised its position in Aptose Biosciences by 40.0% during the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 21,334 shares during the period. Sigma Planning Corp purchased a new position in Aptose Biosciences during the third quarter valued at $408,000. Finally, DRW Securities LLC acquired a new stake in shares of Aptose Biosciences in the fourth quarter valued at about $5,158,000. 26.62% of the stock is owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.